MCID: MYX013
MIFTS: 35

Myxofibrosarcoma malady

Categories: Neuronal diseases, Rare diseases, Skin diseases

Aliases & Classifications for Myxofibrosarcoma

About this section
Sources:
31ICD10 via Orphanet, 54Orphanet, 68UMLS
See all MalaCards sources

Aliases & Descriptions for Myxofibrosarcoma:

Name: Myxofibrosarcoma 54
Fibromyxosarcoma 54 68
 
Dermatofibrosarcoma Protuberans, Myxoid 68
Myxoid Malignant Fibrous Histiocytoma 54

Characteristics:

Orphanet epidemiological data:

54
fibromyxosarcoma:
Inheritance: Not applicable; Age of onset: Adult

Classifications:



External Ids:

Orphanet54 ORPHA79105
ICD10 via Orphanet31 C49.9

Summaries for Myxofibrosarcoma

About this section
Wikipedia:71 A histiocytoma is a tumour consisting of histiocytes. Histiocytes are cells that are a part of the... more...

MalaCards based summary: Myxofibrosarcoma, also known as fibromyxosarcoma, is related to intrahepatic bile duct cystadenoma and myoma. An important gene associated with Myxofibrosarcoma is CREB3L1 (CAMP Responsive Element Binding Protein 3 Like 1), and among its related pathways are Vasopressin-regulated water reabsorption and P38 MAPK Signaling Pathway (sino). Affiliated tissues include heart, skin and breast.

Related Diseases for Myxofibrosarcoma

About this section

Diseases related to Myxofibrosarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 59)
idRelated DiseaseScoreTop Affiliating Genes
1intrahepatic bile duct cystadenoma10.2DES, S100B
2myoma10.2DES, S100B
3spleen angiosarcoma10.2DES, S100B
4ovarian cystadenoma10.2DES, S100B
5biliary papillomatosis10.2DES, S100B
6cavernous sinus meningioma10.2DES, S100B
7bone deterioration disease10.2DES, S100B
8vulvar squamous papilloma10.2DES, S100B
9mediastinum liposarcoma10.2DES, S100B
10dyslexia10.2DES, S100B
11skin glomus tumor10.2DES, S100B
12pustulosis palmaris et plantaris10.2DES, MKI67
13diarrhea, chronic, with villous atrophy10.2DES, S100B
14rectal neoplasm10.2DES, MKI67
15uterine hypoplasia10.2CCNA2, MKI67
16popliteal pterygium syndrome, bartsocas-papas type10.2MKI67, S100B
17his bundle tachycardia10.2MKI67, S100B
18sengers syndrome10.2DES, S100B
19c-p angle neurinoma10.1DES, S100B
20onychocytic matricoma10.1CD36, S100B
21diabetes persistent mullerian ducts10.1DES, S100B
22enchondromatosis dwarfism deafness10.1DES, MKI67, S100B
23cecum adenoma10.1DES, MKI67, S100B
24sarcoma10.1
25gastrointestinal stromal tumor10.1DES, MKI67, S100B
26mediastinum sarcoma10.0CREB3L2, DES
27epimetaphyseal dysplasia cataract10.0MKI67, S100B
28congenital muscular dystrophy with hyperlaxity10.0DES, FUS
29coronary restenosis10.0FUS, S100B
30functionless pituitary adenoma10.0CREB3L2, FUS
31intracranial liposarcoma10.0CREB3L2, FUS
32neutrophil immunodeficiency syndrome10.0DES, S100B
33pinta disease10.0CREB3L2, FUS
34liposarcoma of the ovary9.9CREB3L2, FUS
35liposarcoma9.9
36juvenile xanthogranuloma9.9DES, FUS, S100B
37ehlers-danlos syndrome, cardiac valvular form9.9CD36, CREB3L1
38colorectal cancer 19.9CREB3L2, FUS
39kala-azar 19.9DES, FUS, S100B
40undifferentiated pleomorphic sarcoma9.9
41gestational choriocarcinoma9.8CREB3L2, FUS
42myxoid liposarcoma9.8
43burn scar9.8
44burns9.8
45histiocytoma9.8
46fibrous histiocytoma9.8
47prostate cancer9.6
48dermatofibrosarcoma protuberans9.6
49congestive heart failure9.6
50fibroma9.6

Graphical network of the top 20 diseases related to Myxofibrosarcoma:



Diseases related to myxofibrosarcoma

Symptoms & Phenotypes for Myxofibrosarcoma

About this section

Drugs & Therapeutics for Myxofibrosarcoma

About this section

Drugs for Myxofibrosarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 14)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
IfosfamideapprovedPhase 2, Phase 34003778-73-23690
Synonyms:
(+-)-Ifosfamid
(+-)-Ifosphamide
(+-)-Tetrahydro-N,3-bis(2-chloroethyl)-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
(D,L)-Ifosfamide
(R,S)-Ifosphamide
(R,S)-N,3-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide
1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-, 2-oxide
2,3-(N,N(sup 1)-Bis(2-chloroethyl)diamido)-1,3,2-oxazaphosphoridinoxyd
2,3-N,N(sup 1)-Bis(2-chloroethyl)diamido-1,3,2-oxazaphosphoridinoxyd
2H-1,3,2-Oxazaphosphorin-2-amine, N,3-bis( 2-chloroethyl)tetrahydro-, 2-oxide
2H-1,3,2-Oxazaphosphorin-2-amine, N,3-bis(2-chloroethyl)tetrahydro-, 2-oxide
2H-1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide
2H-1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide (8CI)
2H-1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-, 2-oxide
3,} 2-oxazaphosphorine oxide
3-(2-Chloroethyl)-2-((2-chloroethyl)amino)perhydro-2H-1,3,2-oxazaphosphorine oxide
3-(2-Chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide
3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2H-1,3,2-oxazaphosphorine oxide
3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2H-1,3,2-oxazaphosphorineoxide
3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2- oxide
3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide
36341-88-5
3778-73-2
84711-20-6
A 4942
AB00513932
AC-2113
AC1L1GHW
ASTA Z 4942
Ambap3778-73-2
Asta Z 4942
BPBio1_000865
BRN 0611835
BSPBio_000785
C07047
CAS-3778-73-2
CCRIS 352
CHEBI:5864
CHEMBL1024
CID3690
Cyfos
D00343
D007069
DB01181
EINECS 223-237-3
HMS1570H07
HMS2090M12
HMS2093N07
HSDB 7023
Holoxan
Holoxan 1000
I-Phosphamide
I06-0494
IFEX (TN)
Ifex
Ifosfamid
Ifosfamida
Ifosfamida [INN-Spanish]
Ifosfamide (JAN/USP/INN)
 
Ifosfamide Sterile
Ifosfamide [USAN:INN:BAN:JAN]
Ifosfamidum
Ifosfamidum [INN-Latin]
Ifosphamide
Ifsofamide
Iphosphamid
Iphosphamid(e)
Iphosphamide
Iso Endoxan
Iso-Endoxan
Isoendoxan
Isofosfamide
Isophosphamide
Isosfamide
LS-102
LS-99799
MJF 9325
MJF-9325
MLS002154021
Mitoxana
Mitoxana, Ifex, Ifosfamide
MolPort-003-666-704
N,3-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide
N,3-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
N,N-Bis(beta-chloroethyl)-amino-N',O-propylene-phosphoric acid ester diamide
N-(2-Chloraethyl)-N'-(2-chloraethyl)-N',O-propylen-phosphorsaureester-diamid
N-(2-Chloraethyl)-N'-(2-chloraethyl)-N',O-propylen-phosphorsaureester-diamid [German]
N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylen ephosphoric acid diamide
N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylene phosphoric acid ester diamide
N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylenephosphoric acid diamide
N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylenephosphoric acid ester diamide
N-(2-Chloroethyl)-N-(3-(2-chloroethyl)-2-oxido-1,3,2-oxazaphosphinan-2-yl)amine
NCGC00016639-01
NCGC00179435-01
NCI-C01638
NCI60_000233
NPFAPI-04
NSC 109,724
NSC 109724
NSC-109,724
NSC-109724
NSC109,724
NSC109724
Naxamide
Prestwick0_000833
Prestwick1_000833
Prestwick2_000833
Prestwick3_000833
S1302_Selleck
SMR001233348
SPBio_002706
STL058690
UNII-UM20QQM95Y
WLN: T6NPOTJ AM2G BO B2G
Z 4942
Z-4942
Z4942
ifosfamide
isosfamide
{3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2H-1,
2
MechlorethamineapprovedPhase 2, Phase 339751-75-24033
Synonyms:
.Beta.,.beta.'-Dichlorodiethyl-N-methylamine
1, 5-Dichloro-3-methyl-3-azapentane hydrochloride
126-85-2 (N-oxide)
2,2'-Dichloro-N-me
2,2'-Dichloro-N-methyldiethylamine
2,2'-Dichlorodiethyl-methylamine
2,2'-dichloro-N-methyldiethylamine
2-Chloro-N-(2-chloroethyl)-N-methylethanamine
302-70-5 (N-oxide, hydrochloride)
51-75-2
55-86-7 (HYDROCHLORIDE)
AC1L1H9H
Antimit
BRN 0605323
BSPBio_001947
Bis(2-chloroethyl)methylamine
Bis(beta-chloroethyl) methylamine
Bis(beta-chloroethyl)methylamine
C07115
C5H11Cl2N
CCRIS 447
CHEBI:28925
CHEMBL427
CID4033
Carolysine
Caryolysin
Caryolysine
Chloramine (the nitrogen mustard)
Chlorethazine
Chlormethine
Chlormethine (INN)
Chlormethine [INN:BAN]
Chlormethinum [INN-Latin]
Cloramin
Clormetina
Clormetina [INN-Spanish]
D07671
DB00888
Di(2-chloroethyl)methylamine
Dichlor amine
Dichloren
DivK1c_000759
EINECS 200-120-5
ENT-25294
Embechine
Embichin
HMS1920J15
HMS2091B04
HMS502F21
HN-2
HN2
HSDB 5083
I14-8708
IBS-L0033631
IDI1_000759
KBio1_000759
KBio2_001369
KBio2_003937
KBio2_006505
KBio3_001447
 
KBioGR_001448
KBioSS_001369
LS-7559
MBA
Me chloroethamine
Mebichloramine
Mechlorethamine
Mechlorethanamine
Mechloroethamine
Mecloretamina
Mecloretamina [Italian]
Methylbis(2-chloroethyl)amine
Methylbis(beta-chloroethyl)amine
Methyldi(2-chloroethyl)amine
Mitoxine (*Hydrochloride*)
MolPort-001-785-592
Mustargen
Mustine
Mustine note
Mutagen
N,N-Bis(2-chloroethyl)-N-methylamine
N,N-Bis(2-chloroethyl)methylamine
N,N-Di(chloroethyl)methylamine
N-Lost
N-Methyl lost
N-Methyl-2,2'-dichlorodiethylamine
N-Methyl-bis(2-chloroethyl)amine
N-Methyl-bis(beta-chloroethyl)amine
N-Methyl-bis-chloraethylamin
N-Methyl-bis-chloraethylamin [German]
N-Methyl-lost
N-Methyl-lost [German]
N-methyl-bis(2-chloroethyl)amine
NCGC00091835-02
NCGC00091835-03
NCGC00091835-04
NCGC00091835-05
NCI60_041682
NINDS_000759
NSC762
Nitol (*Hydrochloride*)
Nitrogen mustard
Nitrogen mustard (HN-2)
Nitrogranulogen
SPBio_000496
SPECTRUM1500375
Spectrum2_000448
Spectrum3_000484
Spectrum4_000924
Spectrum5_001702
Spectrum_000889
Stickstofflost (*Hydrochloride*)
Stickstofflost (ebewe)
T 1024
T-1024
TL 146
UNII-50D9XSG0VR
beta,Beta'-dichlorodiethyl-N-methylamine
beta,beta'-Dichlorodiethyl-N-methylamine
mechlorethamine
thyldiethylamine
β,β'-dichlorodiethyl-N-methylamine
3
Cyclophosphamideapproved, investigationalPhase 2, Phase 3293550-18-0, 6055-19-22907
Synonyms:
(+-)-Cyclophosphamide
(-)-Cyclophosphamide
(RS)-Cyclophosphamide
1-(bis(2-chloroethyl)amino)-1-oxo-2-aza-5-oxaphosphoridine
1-Bis(2-chloroethyl)amino-1-oxo-2-aza-5-oxaphosphoridin
2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide
4-Hydroxy-cyclophosphan-mamophosphatide
50-18-0
60007-95-6
6055-19-2 (monohydrate)
75526-90-8
AC1L1EQQ
AI3-26198
ASTA
ASTA B518
Anhydrous cyclophosphamide
Asta B 518
B 518
B-518
BRN 0011744
BSPBio_002099
Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester
C 0768
C07888
C7H15Cl2N2O2P
CB 4564
CB-4564
CCRIS 188
CHEBI:4027
CHEMBL32520
CHEMBL88
CID2907
CP
CPA
CTX
CY
Ciclofosfamida
Ciclofosfamida [INN-Spanish]
Ciclofosfamide
Ciclophosphamide
Ciclophosphamide [INN]
Clafen
Claphene
Cycloblastin
Cyclophosphamid
Cyclophosphamide
Cyclophosphamide (INN)
Cyclophosphamide (TN)
Cyclophosphamide (anhydrous form)
Cyclophosphamide (anhydrous)
Cyclophosphamide Monohydrate
Cyclophosphamide Sterile
Cyclophosphamide anhydrous
Cyclophosphamide, (+-)-Isomer
Cyclophosphamides
Cyclophosphamidum
Cyclophosphamidum [INN-Latin]
Cyclophosphan
Cyclophosphane
Cyclophosphanum
Cyclophosphoramide
Cyclostin
Cyklofosfamid
Cyklofosfamid [Czech]
Cytophosphan
Cytophosphane
Cytoxan
Cytoxan (TN)
Cytoxan Lyoph
D,L-Cyclophosphamide
D07760
 
DB00531
DivK1c_000246
EINECS 200-015-4
EU-0100238
Endoxan
Endoxan R
Endoxan-Asta
Endoxana
Endoxanal
Endoxane
Enduxan
Genoxal
HMS2090A12
HSDB 3047
Hexadrin
IDI1_000246
KBio1_000246
KBio2_001338
KBio2_003906
KBio2_006474
KBio3_001319
KBioGR_000888
KBioSS_001338
LS-1302
LS-99787
Ledoxina
Lopac-C-0768
Lopac0_000238
Lyophilized Cytoxan
Mitoxan
MolPort-001-783-420
N,N-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide
N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
NCGC00015209-01
NCGC00015209-03
NCGC00015209-06
NCGC00091741-02
NCGC00091741-03
NCI-C04900
NCI60_002097
NINDS_000246
NSC 26271
NSC-26271
NSC26271
NSC273033
NSC273034
Neosar
Occupation, cyclophosphamide exposure
Procytox
RCRA waste no. U058
Rcra Waste Number U058
Rcra waste number U058
Revimmune
S1217_Selleck
SK 20501
SPBio_001071
STK177249
STOCK2S-91217
Semdoxan
Sendoxan
Senduxan
Spectrum2_001146
Spectrum3_000370
Spectrum4_000304
Spectrum5_000795
Spectrum_000858
UNII-6UXW23996M
WLN: T6MPOTJ BO BN2G2G
Zyklophosphamid
Zyklophosphamid [German]
bis(2-Chloroethyl)phosphami de cyclic propanolamide
bis(2-Chloroethyl)phosphamide cyclic propanolamide ester
cyclophosphamide
4
Doxorubicinapproved, investigationalPhase 2, Phase 3, Phase 1175123214-92-831703
Synonyms:
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside
(8S-cis)-10-((3-amino-2,3,6-Trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
111266-55-8
14-Hydroxydaunomycin
14-Hydroxydaunorubicine
14-hydroxydaunomycin
14-hydroxydaunorubicine
23214-92-8
23257-17-2
24385-08-8
25311-50-6
25316-40-9
25316-40-9 (hydrochloride)
29042-30-6
AC1L1M5T
AC1Q29OJ
ADM
ADR
Adriablastin
Adriacin (hydrochloride salt)
Adriamycin
Adriamycin PFS
Adriamycin PFS (hydrochloride salt)
Adriamycin RDF
Adriamycin RDF (hydrochloride salt)
Adriamycin Semiquinone
Adriamycin semiquinone
Adriblas tina
Adriblastin
Adriblastina
Adriblastina (TN)
Adriblastina (hydrochloride salt)
Aerosolized Doxorubicin
BPBio1_000502
BRD-K92093830-003-04-3
BSPBio_000456
BSPBio_001031
C01661
C27H29NO11
CCRIS 739
CHEBI:28748
CHEMBL179
CID31703
Caelyx
Conjugate of doxorubicin with humanized monoclonal antibody LL1 against CD74
Conjugate of doxorubicin with monoclonal antibody P4/D10 against GP120
D03899
DB00997
DM2
DOX-SL
Doxil
Doxo
Doxorubicin
Doxorubicin (USAN/INN)
Doxorubicin HCl
 
Doxorubicin Hydrochloride
Doxorubicin [USAN:INN:BAN]
Doxorubicin citrate
Doxorubicin hydrochloride (hydrochloride salt)
Doxorubicin-P4/D10
Doxorubicin-P4/D10 conjugate
Doxorubicin-hLL1
Doxorubicin-hLL1 conjugate
Doxorubicina
Doxorubicina [INN-Spanish]
Doxorubicine
Doxorubicine [INN-French]
Doxorubicinum
Doxorubicinum [INN-Latin]
EINECS 245-495-6
FI 106
Farmablastina (hydrochloride salt)
HMS2089H06
HSDB 3070
Hydroxydaunomycin hydrochlor ide (hydrochloride salt)
Hydroxydaunomycin hydrochloride (hydrochloride salt)
Hydroxydaunorubicin
Hydroxydaunorubicin hydrochloride (hydrochloride salt)
JT9100000
LMPK13050001
LS-1029
LS-165655
MLS000759533
Myocet
NCI-C01514
NChemBio.2007.10-comp13
NDC 38242-874
NIOSH/JT9100000
NSC 123127
Prestwick0_000438
Prestwick1_000438
Prestwick2_000438
Prestwick3_000438
Probes1_000151
Probes2_000129
RDF Rubex
Resmycin
Rubex
Rubex (hydrochloride salt)
SMP1_000106
SPBio_002395
TLC D-99
ThermoDox
Triferric doxorubicin
UNII-80168379AG
adiblastine (hydrochloride salt)
adr iablatina (hydrochloride salt)
adriablastine (hydrochloride salt)
adriablatina (hydrochloride salt)
adriblatina (hydrochloride salt)
doxorubicin
nchembio809-comp5
5
DoxilApproved June 1999Phase 2, Phase 3, Phase 1175131703
Synonyms:
Dox-SL
Doxil
 
Evacet
LipoDox
Pegylated Liposomal Doxorubicin Hydrochloride
liposomal doxorubicin
6Anti-Bacterial AgentsPhase 2, Phase 3, Phase 111226
7Topoisomerase InhibitorsPhase 2, Phase 3, Phase 15069
8Antineoplastic Agents, AlkylatingPhase 2, Phase 34603
9Isophosphamide mustardPhase 2, Phase 3400
10Antibiotics, AntitubercularPhase 2, Phase 3, Phase 17180
11Alkylating AgentsPhase 2, Phase 34827
12razoxanePhase 243
13Antimitotic AgentsPhase 25657
14Protective AgentsPhase 27443

Interventional clinical trials:

idNameStatusNCT IDPhase
1Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-Rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by SurgeryRecruitingNCT02180867Phase 2, Phase 3
2Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic SarcomaRecruitingNCT02601209Phase 1, Phase 2
3Doxorubicin With Upfront Dexrazoxane Plus Olaratumab for the Treatment of Advanced or Metastatic Soft Tissue SarcomaRecruitingNCT02584309Phase 2
4Alisertib in Treating Patients With Advanced or Metastatic SarcomaActive, not recruitingNCT01653028Phase 2
5Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by SurgeryRecruitingNCT03009201Phase 1

Search NIH Clinical Center for Myxofibrosarcoma

Genetic Tests for Myxofibrosarcoma

About this section

Anatomical Context for Myxofibrosarcoma

About this section

MalaCards organs/tissues related to Myxofibrosarcoma:

36
Heart, Skin, Breast, Lung, Brain, Prostate, Skeletal muscle

Publications for Myxofibrosarcoma

About this section

Articles related to Myxofibrosarcoma:

(show top 50)    (show all 171)
idTitleAuthorsYear
1
A histological positive margin after surgery is correlated with high local re-recurrence rate in patients with recurrent myxofibrosarcoma. (28064204)
2017
2
A Case of Myxofibrosarcoma in an Unusual Thoracic Location. (26933417)
2016
3
Tail of Superficial Myxofibrosarcoma and Undifferentiated Pleomorphic Sarcoma After Preoperative Radiotherapy. (27127141)
2016
4
Massively Distended Abdomen Caused by Fibromatosis Previously Misdiagnosed as Myxofibrosarcoma. (27858546)
2016
5
Myxofibrosarcoma in the Thenar Eminence. (27505448)
2016
6
Modified partial maxillary swing approach for myxofibrosarcoma in pterygopalatine fossa. (27501198)
2016
7
Myxofibrosarcoma. (27591498)
2016
8
Myxofibrosarcoma of the extremity and trunk: a multidisciplinary approach leads to good local rates of LOCAL control. (27909132)
2016
9
An unexpected skin ulcer and soft tissue necrosis after the nonconcurrent combination of proton beam therapy and pazopanib: A case of myxofibrosarcoma. (27523716)
2016
10
Myxofibrosarcoma presenting as an exophytic, multi-lobed nodule on the leg. (27617600)
2016
11
A case report of primary cardiac myxofibrosarcoma presenting with severe congestive heart failure. (27387491)
2016
12
Primary cardiac myxofibrosarcoma in a young woman. (27594370)
2016
13
Giant myxofibrosarcoma of the orbit: a rare case and a review of the literature. (27298287)
2016
14
Myxofibrosarcoma of the heart: A case report with positive pleural effusion cytology. (27546198)
2016
15
Soft tissue myxofibrosarcoma: A clinico-pathological analysis of a series of 75 patients with emphasis on the epithelioid variant. (27076198)
2016
16
Surgical margins do not affect prognosis in high grade myxofibrosarcoma. (27260849)
2016
17
Integrin-I+10 Dependency Identifies RAC and RICTOR as Therapeutic Targets in High-Grade Myxofibrosarcoma. (27577794)
2016
18
Optimal Percent Myxoid Component to Predict Outcome in High-Grade Myxofibrosarcoma and Undifferentiated Pleomorphic Sarcoma. (26759307)
2016
19
Myxofibrosarcoma - Case report. (26982788)
2016
20
Right cardiac intracavitary metastases from a primary intracranial myxofibrosarcoma. (27013654)
2016
21
Coronary thrombus aspiration revealed tumorous embolism of myxofibrosarcoma from the left atrium. (25711731)
2015
22
Primary renal myxofibrosarcoma. (26008776)
2015
23
Cell cycle and apoptosis regulatory proteins, proliferative markers, cell signaling molecules, CD209, and decorin immunoreactivity in low-grade myxofibrosarcoma and myxoma. (25940995)
2015
24
High-grade myxofibrosarcoma-presented as a large mass of right upper arm. (25673608)
2015
25
Intramuscular high-grade myxofibrosarcoma of left buttock of 66-year-old male patient - approach to systematic histopathological reporting. (26743304)
2015
26
Prognostic impact of CD109 expression in myxofibrosarcoma. (26031650)
2015
27
Low-grade myxofibrosarcoma following a metal implantation in femur: a case report. (24444015)
2014
28
Very rare case of large obstructive myxofibrosarcoma of the right ventricle assessed with multi-diagnostic imaging techniques. (24694488)
2014
29
Clinical aggressiveness of myxofibrosarcomas associates with down-regulation of p12CDK2AP1: prognostic implication of a putative tumor suppressor that induces cell cycle arrest and apoptosis via mitochondrial pathway. (24889487)
2014
30
Paratesticular myxofibrosarcoma. (25118763)
2014
31
MR imaging of myxofibrosarcoma and undifferentiated sarcoma with emphasis on tail sign; diagnostic and prognostic value. (24889995)
2014
32
Short-term spontaneous regression of myxofibrosarcoma in the scapular region. (24910124)
2014
33
Metachronous Myxofibrosarcoma and Osteosarcoma: Case Report and Review of the Literature. (24891554)
2014
34
Increased CD44s and decreased CD44v6 RNA expression are associated with better survival in myxofibrosarcoma patients: a pilot study. (24491153)
2014
35
Downregulated MTAP expression in myxofibrosarcoma: A characterization of inactivating mechanisms, tumor suppressive function, and therapeutic relevance. (25426549)
2014
36
Immunohistochemical analysis of expressions of RB1, CDK4, HSP90, cPLA2G4A, and CHMP2B is helpful in distinction between myxofibrosarcoma and myxoid liposarcoma. (24788530)
2014
37
High-dose-rate Interstitial Brachytherapy Boost with a Pedicled Latissimus Dorsi Myocutaneous Flap for Myxofibrosarcoma of the Arm. (25426346)
2014
38
Head and neck myxofibrosarcoma: a case report and review of the literature. (25547541)
2014
39
Myxofibrosarcoma with associated Mycobacterium infection. (24966999)
2014
40
Myxofibrosarcoma arising in a burn scar. (24354641)
2014
41
The management of myxofibrosarcoma - a ten-year experience in a single specialist centre. (26280619)
2014
42
Impact of infiltrative growth on the outcome of patients with undifferentiated pleomorphic sarcoma and myxofibrosarcoma. (24975462)
2014
43
An analysis of factors related to the tail-like pattern of myxofibrosarcoma seen on MRI. (25172220)
2014
44
Appearance of recurrent cardiac myxofibrosarcoma on FDG PET/CT. (24662649)
2014
45
Myxofibrosarcoma directly invading superior vena cava causing obstruction successfully relieved by endovascular stent. (25365347)
2014
46
Primary intermediate-grade cardiac myxofibrosarcoma with osseous metaplasia: an extremely rare occurrence with a previously unreported feature. (25246023)
2014
47
Orbital myxofibrosarcoma: a clinicopathologic correlation of an extremely rare tumor. (24833459)
2014
48
Myxofibrosarcoma of the thyroid gland. (24702999)
2014
49
AMACR amplification in myxofibrosarcomas: a mechanism of overexpression that promotes cell proliferation with therapeutic relevance. (25384383)
2014
50
Myxofibrosarcoma arising from a chronic burn scar. (24506764)
2014

Variations for Myxofibrosarcoma

About this section

Copy number variations for Myxofibrosarcoma from CNVD:

6 (show all 47)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1297051234600000241700000LossAKT3Myxofibrosarcoma
23887510105700000114900000LossFACL5Myxofibrosarcoma
33942310114900000127400000LossDMBT1Myxofibrosarcoma
4426871038000006700000LossDNMT2Myxofibrosarcoma
5478031098000000105700000LossHOX11Myxofibrosarcoma
6478051098000000105700000LossPLAUMyxofibrosarcoma
74968711110000000120700000LossPIG8Myxofibrosarcoma
85175711130300000134452384LossADAMTS8Myxofibrosarcoma
954382114340000048800000LossKAI1Myxofibrosarcoma
106147412114800000GainCCND2Myxofibrosarcoma
116152212133200000LossLRP6Myxofibrosarcoma
1266186122630000033200000GainKRAGMyxofibrosarcoma
1370913126600000069800000GainHMGICMyxofibrosarcoma
1473112129120000094800000LossBTG1Myxofibrosarcoma
15108897172320000035400000LossLIG3Myxofibrosarcoma
16115128175490000059900000GainTBX2Myxofibrosarcoma
171241761916900000GainSH3GL1Myxofibrosarcoma
1814368122390000031900000LossALKMyxofibrosarcoma
19147727269800000136600000LossCXCR4Myxofibrosarcoma
2014830327540000083700000LossREG1AMyxofibrosarcoma
21151117201780000027100000LossJAG1Myxofibrosarcoma
221708943161200000184200000LossMDS1Myxofibrosarcoma
2317756735850000063700000LossFHITMyxofibrosarcoma
24186568436900000114100000LossIBSPMyxofibrosarcoma
2518754145070000052400000GainAFPMyxofibrosarcoma
262080646164400000170899992LossPDCD2Myxofibrosarcoma
272178487104755715105039798AmplificationlicationSRPK2Myxofibrosarcoma
282179237105888733105925638AmplificationlicationPBEF1Myxofibrosarcoma
292181147107788083108096826AmplificationlicationNRCAMMyxofibrosarcoma
302186927116312458116438439AmplificationlicationMETMyxofibrosarcoma
312190527121513158121702088AmplificationlicationPTPRZ1Myxofibrosarcoma
322192577124462440124570037AmplificationlicationPOT1Myxofibrosarcoma
332194807127292201127732658AmplificationlicationSND1Myxofibrosarcoma
342199537132400000147500000GainTIM1Myxofibrosarcoma
35223288718554272272583Amplificationlicatio nMAD1L1Myxofibrosarcoma
3622554874731475247621742AmplificationTNS3Myxofibrosarcoma
3722804477324519273247014Amplificationlicatio nCLDN4Myxofibrosarcoma
3822877278133144481399452Amplificationlicatio nHGFMyxofibrosarcoma
3922910478725772887461612Amplificationlicatio nRPIP9Myxofibrosarcoma
4022933279009573790839904Amplificationlicatio nPFTK1Myxofibrosarcoma
4122960079223423692465941Amplificationlicatio nCDK6Myxofibrosarcoma
422349538140000000146274826GainTGMyxofibrosarcoma
432423858720000043200000GainPOLBMyxofibrosarcoma
44262150X3150000037500000GainOTCMyxofibrosarcoma
45264432X6510000067700000GainED1Myxofibrosarcoma
46264546X6770000072200000GainTEDMyxofibrosarcoma
47266520X98200000110500000LossPLPMyxofibrosarcoma

Expression for genes affiliated with Myxofibrosarcoma

About this section
Search GEO for disease gene expression data for Myxofibrosarcoma.

Pathways for genes affiliated with Myxofibrosarcoma

About this section

GO Terms for genes affiliated with Myxofibrosarcoma

About this section

Biological processes related to Myxofibrosarcoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1endoplasmic reticulum unfolded protein responseGO:003096810.2CREB3L1, CREB3L2
2response to unfolded proteinGO:00069869.7CREB3L1, CREB3L2
3animal organ regenerationGO:00311009.6CCNA2, MKI67

Molecular functions related to Myxofibrosarcoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1cAMP response element bindingGO:00354979.7CREB3L1, CREB3L2

Sources for Myxofibrosarcoma

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet